MediciNova(MNOV)

Focus: MediciNova is a public-stage biotech company focused on small-molecule therapeutics across respiratory, neurology, infectious diseases, oncology, and metabolic disease indications. The company operates as a clinical-stage developer with a diversified pipeline but minimal revenue generation.

Respiratory Neurology Infectious Diseases Oncology

Profile data last refreshed 3m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About MediciNova

AI assessmentNot Hiring

No open roles listed right now. Follow MediciNova to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

21 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$410K

Pipeline & Clinical Trials

MN-166

ALS

N/A

Clinical Trials (1)

NCT06743776Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

N/A

Help build intelligence for MediciNova

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline across 5 therapeutic areas with 21 active trials provides exposure to multiple disease states and clinical development phases
Public company status with $40M cash runway enables medium-term employment stability and potential equity upside if pipeline progresses
Small-molecule focus offers focused technical expertise domain compared to broader platforms

Watch Out For

Near-zero revenue ($410K in FY2025) with $11M annual net losses and declining cash reserves ($40M down from $51M) signal financial stress within 3-4 years
Zero active job postings and no headcount data suggest minimal hiring, contradicting growth narratives
Extremely high R&D intensity (1660% of revenue) indicates the company is burning cash faster than it generates—unsustainable without major financing or clinical win

Generated by Claude from MediciNova's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

MN-166

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04054206Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

Phase 1

MN-166

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03533387Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Phase 1

MN-221

Chronic Obstructive Pulmonary Disease

PHASE_1

Clinical Trials (1)

NCT01013142Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

MN-221

Chronic Obstructive Pulmonary Disease

PHASE_1

Clinical Trials (1)

NCT01551316Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 1

Ibudilast 20mg

Methamphetamine-dependence

PHASE_1

MN-166

Glioblastoma

PHASE_1_2

Clinical Trials (1)

NCT03782415Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Phase 1/2

ibudilast

Amyotrophic Lateral Sclerosis

PHASE_1_2

Clinical Trials (1)

NCT02714036A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

Phase 1/2

MN-001 BID

Interstitial Cystitis

PHASE_2

Clinical Trials (1)

NCT00295854Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Phase 2

Dose Group 1

Asthma

PHASE_2

Clinical Trials (1)

NCT00683449Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

Phase 2

Ibudilast

Alcohol Use Disorder

PHASE_2

MN-001

Non-alcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT02681055Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

Phase 2

MN-166

Opioid Abuse

PHASE_2

Clinical Trials (1)

NCT01740414Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

Phase 2

ibudilast

Multiple Sclerosis, Primary Progressive

PHASE_2

Clinical Trials (1)

NCT01982942Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Phase 2

MN-221

Asthma

PHASE_2

Clinical Trials (1)

NCT00679263Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Phase 2

Placebo

Amyotrophic Lateral Sclerosis

PHASE_2

Clinical Trials (1)

NCT02238626Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

MN-001

Idiopathic Pulmonary Fibrosis

PHASE_2

Clinical Trials (1)

NCT02503657Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

Phase 2

MN-221

Asthma

PHASE_2

Clinical Trials (1)

NCT00838591Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

Phase 2

MN-001

Diabetes Mellitus, Type 2

PHASE_2

Clinical Trials (1)

NCT05464784MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Phase 2

Ibudilast

Pneumonia, Viral

PHASE_2

Clinical Trials (1)

NCT04429555Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Phase 2

MN-166

Amyotrophic Lateral Sclerosis

PHASE_2_3

Clinical Trials (1)

NCT04057898Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 19 clinical trials

Top TAs: Respiratory, Neurology, Infectious Diseases

Publications: 16 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

6 pipeline

4 pipeline

2 pipeline

2 pipeline

1 pipeline

Financials (FY2025)

Revenue

$410K59%

R&D Spend

$7M(1660%)28%

Net Income

-$11M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study.

BMC pulmonary medicine

2026

PMID:41928198

Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis.